Global Cell Line Development Market Size (2024 - 2029)

Cell Line Development Market Analysis

Cell Line Development Market is poised to grow at a CAGR of 10.6% over the forecast period (2022-2027).

In March 2020, the World Health Organization (WHO) classified COVID-19 as a pandemic. Since that time, the mortality rate from chronic diseases has grown dramatically. As a result of the rising demand for vaccine development, COVID-19 is seen to have a positive effect on the cell line development industry. According to the study titled "Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening" published in the Journal of Virus in March 2022, Researchers have described the creation of a suitable human cell line for the high-throughput testing of antiviral medications that target the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2). Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), two essential host proteins required for viral entry, were engineered to express high levels in the human lung carcinoma cell line A549. As a result, more cell lines are being developed to manage COVID-19, which had a significant impact on the market under study during the pandemic.

The market is driven by the growing biopharmaceutical industry, rising demand for monoclonal antibodies and cancer therapeutics, and growing production of biosimilars due to the patent expiry of branded therapeutics.

Due to changes in dietary practises, a lack of physical activity, and general changes in lifestyle, cancer has become more prevalent over the past ten years. In addition, the demand for cell line development will rise as vaccine production expands and technology advances. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounts to around 19.29 million cases. The number is estimated to rise to 28.89 million cases by 2040. The use of cell lines in the production of biological cancer drug substances is increased due to increasing in cancer burden hence the cell line development market is expected to grow over the projecting period.

Moreover, growing production of biosimilars due to the patent expiry of branded therapeutics is expected to drive the growth of the market. cell line development play an important role in manufacturing and development of the biosimilars. Biosimilars increase market competition and facilitate patient access to life-saving medications. The primary objective of biosimilar producers is to lower treatment costs. For instance, according to the study titled "Expected Impact of Biosimilars on the Pharmaceutical Companies" published in the Iranian Journal of Medical Science in September 2021, In the markets of France, Germany, Italy, Spain, and the UK, patients now have a 44% greater access to these products as a result of the introduction of biosimilars in the European Union (EU). Therefore, it is anticipated that the development of biosimilar products will increase, making therapeutics more accessible to the individual and accelerating market growth. Moreover, growing launch of the biosimilars expected to accelerate the market growth. For instance, in June 2022, Biogen and Samsung Bioepis reported that Byooviz (ranibizumab-nuna) has been launched on the United States market as ophthalmology biosimilar.Thus, increasing biosimilar launches and patent expirations both had positive effects on market growth.

The above-mentioned statistics indicate the high burden of cancer across the world, which is expected to drive the growth of cell line development market, as there is been an increasing demand for the novel therapeutics to deal with cancer.

Cell Line Development Industry Segmentation

As per the scope of this report, the cell line development market includes the types of equipment that have been used in the process along with the source from where the cell is extracted. Furthermore, the market studied includes different types of cell lines and the end users of the same. The Cell Line Development Market is segmented by Product (Reagents and Media, Equipment, Finished Cells, and Other Products), Source (Mammalian Cell Line, Non-mammalian Cell Line), Application (Recombinant Protein Expression, Hybridomas Technology, Vaccine Production, Drug Discovery, Other Applications) End User (Biotech and Pharmaceutical Companies, Academics and Research Institutes, Other End Users) and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.